Research priorities for Chagas disease, human African trypanosomiasis and leishmaniasis : technical report of the TDR Disease Reference Group on Chagas Disease, Human African Trypanosomiasis and Leishmaniasis.
"This report provides a review and analysis of the research landscape for three diseases--Chagas disease, human African Trypanosomiasis and leishmaniasis--that dispropotionally afflict poor and remote populations with limited access to health services. It represents the work of the disease refe...
Saved in:
| Corporate Authors: | , |
|---|---|
| Other title: | Research priorities for Chagas disease, HAT and Leishmaniasis. Technical report of the TDR Disease Reference Group on Chagas Disease, Human African Trypanosomiasis and Leishmaniasis. |
| Format: | Book |
| Language: | English |
| Published: |
Geneva, Switzerland :
World Health Organization,
©2012.
|
| Series: | Technical report series (World Health Organization) ;
975. |
| Subjects: |
MARC
| LEADER | 00000cam a2200000Ia 4500 | ||
|---|---|---|---|
| 001 | b7587540 | ||
| 003 | CoU | ||
| 005 | 20131011110757.0 | ||
| 008 | 130221s2012 sz b b i000 0 eng d | ||
| 019 | |a 828891528 |a 835917100 |a 839394380 | ||
| 020 | |a 9789241209755 | ||
| 020 | |a 9241209755 | ||
| 035 | |a (OCoLC)ocn828148417 | ||
| 035 | |a (OCoLC)828148417 |z (OCoLC)828891528 |z (OCoLC)835917100 |z (OCoLC)839394380 | ||
| 040 | |a TML |c TML |d TML |d TPH |d ORU |d YDXCP |d VGM |d AU@ |d OCLCO |d BTCTA | ||
| 049 | |a COD8 | ||
| 099 | |a 1000 |a W65 |a T226 |a no.975 |a 2012 | ||
| 245 | 0 | 0 | |a Research priorities for Chagas disease, human African trypanosomiasis and leishmaniasis : |b technical report of the TDR Disease Reference Group on Chagas Disease, Human African Trypanosomiasis and Leishmaniasis. |
| 246 | 1 | 8 | |a Research priorities for Chagas disease, HAT and Leishmaniasis. |
| 246 | 1 | |a Technical report of the TDR Disease Reference Group on Chagas Disease, Human African Trypanosomiasis and Leishmaniasis. | |
| 260 | |a Geneva, Switzerland : |b World Health Organization, |c ©2012. | ||
| 300 | |a xii, 100 pages : |b maps ; |c 24 cm. | ||
| 336 | |a text |b txt |2 rdacontent. | ||
| 337 | |a unmediated |b n |2 rdamedia. | ||
| 338 | |a volume |b nc |2 rdacarrier. | ||
| 490 | 1 | |a WHO technical report series ; |v 975. | |
| 505 | 0 | |a 1. Introduction -- 1.1 Reasons for setting research priorities -- 1.2 TDR stewardship mandate -- 1.3 Goal of this report /strategic objectives -- 1.4 Overview -- 2. Methodology and prioritization -- 2.1 Authoritative evidence review to define thematic areas -- 2.2 Stakeholders' consultation and second round of criteria-based ranking -- 2.3 Final round of ranking -- 3. Epidemiology and burden of disease -- 3.1 Chagas disease -- 3.2 Human African trypanosomiasis -- 3.3 Leishmaniasis -- 4. Clinical forms, pathogenesis and HIV coinfection -- 4.1 Chagas disease -- 4.1.1 Clinical presentations -- 4.1.2 Chagas heart disease -- 4.1.3 Gastrointestinal manifestations -- 4.1.4 Congenital Chagas disease -- 4.1.5 Chagas disease and HIV coinfection -- 4.2 Human African trypanosomiasis -- 4.2.1 Pathogenesis -- 4.2.2 Clinical presentation -- 4.3 Leishmaniasis -- 4.3.1 Clinical presentations -- 5. Diagnosis -- 5.1 Chagas disease -- 5.1.1 Parasitological diagnosis -- 5.1.2 Serology -- 5.1.3 Quantitative and qualitative detection of parasite DNA -- 5.1.4 Diagnosis in newborns -- 5.1.5 Diagnosis of therapy efficacy and cure -- 5.1.6 Diagnosis of drug resistant Chagas disease -- 5.2 Human African trypanosomiasis -- 5.2.1 Demonstration of parasite -- 5.2.2 Serology -- 5.2.3 Quantitative and qualitative detection of parasite DNA -- 5.2.4 Staging of the disease -- 5.3 Leishmaniasis -- 5.3.1 Parasitological diagnosis -- 5.3.2 Serology -- 5.3.3 Detection of parasite products -- 5.3.4 Quantitative and qualitative detection of parasite DNA -- 6. Drugs and drug resistance -- 6.1 Current treatment and development of new drugs -- 6.1.1 Chagas disease -- 6.1.2 Human African trypanosomiasis -- 6.1.3 Leishmaniasis -- 7. Vaccines against Chagas disease, human African trypanosomiasis and leishmaniasis -- 7.1 Overview -- 7.2 Chagas disease -- 7.3 Human African trypanosomiasis -- 7.4 Leishmaniasis -- 8. Vector control -- 8.1 Chagas disease: triatomine bug control -- 8.2 Human African trypanosomiasis: tsetse fly control -- 8.2.1 Tsetse species of highest priority -- 8.2.2 Control activities at all levels -- 8.2.3 Costs of vector control -- 8.3 Leishmaniasis: sandfly control -- 8.3.1 Source reduction -- 8.3.2 Targeting sugar-feeding adult sandflies -- 8.3.3 Extermination of sandflies feeding on domestic animals -- 8.3.4 Flight barriers for preventing sandflies from reaching houses -- 8.3.5 Protection of homes--indoor residual insecticide spraying -- 8.3.6 Protection of rooms/porches--insecticide diffusers and coils -- 8.3.7 Personal protection--insecticide-treated nets and repellents -- 8.3.8 Integrated disease-control campaigns -- 9. Economic evaluation of health-care interventions -- 10. Research priority recommendations. | |
| 504 | |a Includes bibliographical references (pages 85-97) | ||
| 520 | |a "This report provides a review and analysis of the research landscape for three diseases--Chagas disease, human African Trypanosomiasis and leishmaniasis--that dispropotionally afflict poor and remote populations with limited access to health services. It represents the work of the disease reference group on Chagas Disease, human African Trypanosomiasis, and leishmaniasis (DRG3) which was established to identify key research priorities through review of research evidence and input from stakeholders' consultations. The diseases, which are caused by related protozoan parasites, are described in terms of their epidemiology and disease burden, clinical forms and pathogenesis, HIV coinfection, diagnosis, drugs and drug resistance, vaccines, vector control, and health-care interventions. Priority areas for research are identified based on criteria such as public health relevance, benefit and impact on poor populations and equity, and feasibility. The priorities are found in the areas of diagnostics, drugs, vector control, asymptomatic infection, economic analysis of treatment and vector control methods, and in some specific issues such as surveillance methods or transmission-blocking vaccines for particular diseases. This report will be useful to researchers, policy and decision makers, funding bodies, implementation organizations, and civil society."--P. 4 of cover. | ||
| 530 | |a Also available online. | ||
| 650 | 1 | 2 | |a Chagas Disease. |
| 650 | 1 | 2 | |a Chagas Disease |x diagnosis. |
| 650 | 1 | 2 | |a Chagas Disease |x transmission. |
| 650 | 1 | 2 | |a Chagas Disease |x prevention & control. |
| 650 | 1 | 2 | |a Trypanosomiasis, African |x diagnosis. |
| 650 | 1 | 2 | |a Trypanosomiasis, African |x transmission. |
| 650 | 1 | 2 | |a Trypanosomiasis, African |x prevention & control. |
| 650 | 1 | 2 | |a Leishmaniasis |x diagnosis. |
| 650 | 1 | 2 | |a Leishmaniasis |x transmission. |
| 650 | 1 | 2 | |a Leishmaniasis |x prevention & control. |
| 650 | 2 | 2 | |a Drug Resistance. |
| 650 | 2 | 2 | |a Vaccines. |
| 650 | 2 | 2 | |a Tropical Medicine. |
| 650 | 0 | |a Chagas' disease. |0 http://id.loc.gov/authorities/subjects/sh85022320. | |
| 650 | 0 | |a Chagas' disease |x Diagnosis. | |
| 650 | 0 | |a Chagas' disease |x Prevention. | |
| 650 | 0 | |a Chagas' disease |x Transmission. | |
| 650 | 0 | |a African trypanosomiasis. |0 http://id.loc.gov/authorities/subjects/sh85001750. | |
| 650 | 0 | |a African trypanosomiasis |x Diagnosis. | |
| 650 | 0 | |a African trypanosomiasis |x Prevention. | |
| 650 | 0 | |a African trypanosomiasis |x Transmission. | |
| 650 | 0 | |a Leishmaniasis. |0 http://id.loc.gov/authorities/subjects/sh85075922. | |
| 650 | 0 | |a Leishmaniasis |x Diagnosis. | |
| 650 | 0 | |a Leishmaniasis |x Prevention. | |
| 650 | 0 | |a Leishmaniasis |x Transmission. | |
| 710 | 2 | |a TDR Disease Reference Group on Chagas Disease, Human African Trypanosomiasis and Leishmaniasis. |0 http://id.loc.gov/authorities/names/no2013114142. | |
| 710 | 2 | |a World Health Organization. |0 http://id.loc.gov/authorities/names/n79059041 |1 http://isni.org/isni/0000000121633745. | |
| 830 | 0 | |a Technical report series (World Health Organization) ; |v 975. |0 http://id.loc.gov/authorities/names/n83706379. | |
| 907 | |a .b75875408 |b 03-19-20 |c 10-11-13 | ||
| 998 | |a gov |b 10-17-13 |c a |d m |e - |f eng |g sz |h 0 |i 1 | ||
| 907 | |a .b75875408 |b 11-27-14 |c 10-11-13 | ||
| 944 | |a MARS - RDA ENRICHED | ||
| 907 | |a .b75875408 |b 11-04-13 |c 10-11-13 | ||
| 907 | |a .b75875408 |b 10-17-13 |c 10-11-13 | ||
| 946 | |a ym | ||
| 999 | f | f | |i 610efb09-39e9-5970-875c-f830093927c1 |s 942319d3-2823-599d-81af-b1bd4195c4ce |
| 952 | f | f | |p Can circulate |a University of Colorado Boulder |b Boulder Campus |c Norlin |d Norlin Library - Government Information - International |e 1000 W65 T226 no.975 2012 |h Other scheme |i document |m U183051492080 |n 1 |